Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses the role of measurable residual disease (MRD) in drug development and treatment monitoring for multiple myeloma (MM). Advances in technology have improved MRD detection accuracy, leading to its accelerated approval as an early endpoint in clinical trials. Dr Landgren emphasizes the need for blood-based MRD monitoring tools, as bone marrow biopsies are not feasible for routine use. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.